More French Early Abortion Patients Select Medical Abortion than Surgery, but Dissatisfaction Is Greater

1992 ◽  
Vol 24 (6) ◽  
pp. 278
Author(s):  
R. Turner
Sexual Health ◽  
2007 ◽  
Vol 4 (4) ◽  
pp. 223 ◽  
Author(s):  
Caroline M. de Costa ◽  
Darren B. Russell ◽  
Naomi R. de Costa ◽  
Michael Carrette ◽  
Heather M. McNamee

Recent changes to Federal Therapeutic Goods Administration legislation have seen the limited introduction of the drug mifepristone to Australia for the purpose of early medical abortion. At the same time it has become evident that both methotrexate and misoprostol, licenced and available for other indications, are being used safely and appropriately for early abortion by Australian medical practitioners. Early medical abortion is widely practiced overseas where its safety and effectiveness are well supported by current evidence. However, abortion law in many states is still contained within the Criminal Codes and does not reflect current evidence-based abortion practice. In other states and territories restrictions on where abortions may be performed pose potential barriers to the introduction of mifepristone for medical abortion. There is an urgent need for abortion law to be clarified and made uniform across the country so that the best possible services can be provided to Australian women.


Author(s):  
Mehvish Anjum ◽  
Nivedita D.

Background: Medical abortion or Medical Methods of abortion (MMA) (or Chemical abortion) is defined as “the non-surgical way of termination of termination of pregnancy by a drug or combination of drugs”. With introduction of MMA there has been a steep rise in abortion related complications due to irrational use of these drugs. This study is undertaken using lowest effective dose of mifepristone and misoprostol in 100 women willing for termination of pregnancy with period of gestation <49 days to study the efficacy, side effects and failure rate. Present study emphasizes on using MMA by proper selection of patient, adhering to proper schedule under provision of MTP Act (counselling, consent, examination, confirmation of pregnancy, prescription by a registered medical practioner) in order to enhance efficacy and avoid complications.Methods: Prospective Clinical Study consist of use of single dose of 200mg of mifepristone orally followed by misoprostol (400µg) by vaginal route for terminating pregnancy in ≤49 days of gestation. Statistical analysis done by Chi square test.Results: In this study, success rate i.e. complete abortion without requiring surgical procedure was 96%and failure rate was 4%. Nausea (56%) is the most common side effect of Mifepristone. Chills (33%) is the most common side effect of Misoprostol. Mean Induction Abortion Interval is 2.17±1.2 hrs. Mean Duration of Bleeding is 7.79±4.42 days.Conclusions: Medical abortion is a promising method of early abortion in a developing country like India as it requires no technical skills and manpower with a good safety profile.


1970 ◽  
Vol 8 (3) ◽  
pp. 142-146
Author(s):  
Ajay Agrawal ◽  
Mohan C Regmi ◽  
Dhruba Kumar Uprety ◽  
Hanoon Pokhrel ◽  
Pappu Rijal

Objective: To test the feasibility and acceptability of a simplified mifepristone-misoprostol regimen for early abortion at BPKIHS.Methods: Pregnant women (n=100) with amenorrhea of 56 days or less seeking termination of pregnancy received 200mg of oral mifepristone followed 48hours later by 400 μg of oral misoprostol, administered either at home or at the clinic. Prospective data were collected to determine the women.s experience, abortion outcome, and the operational requirement for providing the method.Result: Most (91%) of the 88 women with known outcomes had successful medical abortions. Given the option, most (95.4%) women elected to administer the misoprostol at home. Conclusion: A simplified medical abortion protocol, including home administration of misoprostol, is highly safe, effective acceptable and feasible in our setting. Keywords: medical abortion; mifepristone; misoprostol DOI: 10.3126/hren.v8i3.4205Health Renaissance, September-December 2010; Vol 8 (No.3);142-146


2016 ◽  
Vol 4 (1) ◽  
pp. 9 ◽  
Author(s):  
Aneta Tomescu ◽  
Rodica Sîrbu ◽  
Stelian Paris ◽  
Emin Cadar ◽  
Cristina Luiza Erimia ◽  
...  

Our study is a rewiew of Methotrexate therapy in obstetrica? diseases such us: hydatidiform mole, and medical abortion. In the medical world, methotrexate is a citostatic drug used in neoplastic diseases. The clinical pharmacology data regarding methotrexate is presented, alongside route of administration and therapeutic effects in malignant disease, hydatiform mole, and medical abortion. The use of methotrexate in medical abortion and ectopic pregnancy is a great accomplishment, as it replaces a surgical intervention marred by characteristic side effects, with similar results.


2016 ◽  
Vol 2 (1) ◽  
pp. 9 ◽  
Author(s):  
Aneta Tomescu ◽  
Rodica Sîrbu ◽  
Stelian Paris ◽  
Emin Cadar ◽  
Cristina Luiza Erimia ◽  
...  

Our study is a rewiew of Methotrexate therapy in obstetrica? diseases such us: hydatidiform mole, and medical abortion. In the medical world, methotrexate is a citostatic drug used in neoplastic diseases. The clinical pharmacology data regarding methotrexate is presented, alongside route of administration and therapeutic effects in malignant disease, hydatiform mole, and medical abortion. The use of methotrexate in medical abortion and ectopic pregnancy is a great accomplishment, as it replaces a surgical intervention marred by characteristic side effects, with similar results.


Sign in / Sign up

Export Citation Format

Share Document